|
|
Article: Cancer drug rule 'overdue' ; A decision to allow patients with advanced kidney cancer to access a new drug is "shamefully long overdue", a leading Westcountry health campaigner said yesterday.
- Article from:
- Western Morning News, The Plymouth (UK)
- Article date:
- February 5, 2009
- Author:
CopyrightCopyright 2009 Western Morning News, The Plymouth (UK). Provided by ProQuest LLC. (Hide copyright information)
|
A decision to allow patients with advanced kidney cancer to
access a new drug is "shamefully long overdue", a leading
Westcountry health campaigner said yesterday.
The National Institute for Health and Clinical Excellence (Nice)
yesterday published revised guidance on the drug Sutent.
Similar advice published last year rejected the drug for use on
the NHS, alongside Avastin, Nexavar and Torisel. Health charities
were outraged at that decision, saying it left patients only one
treatment option, Interferon, to which many people do not respond.
Nice has now revised its guidance, saying Sutent should be
approved on the NHS in England but still rejected the other three
drugs.
The medicines do not ...